I usually have a lot to say. I just know when to keep it to myself.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fantastic, berge! You may need this link:
http://www.tiffany.com/shopping/category.aspx?menu=1&cid=96688&mcat=148204&isMenu=1
I'm curious for America to vote :) Perhaps it will be Fat Cats Idol.
AFTERHOURS: ICON (chart at bottom of post) Iconix Brand Group Signs Direct-to-Retail License
for its Ocean Pacific(R) and OP Brands(R) With Wal-Mart
Monday August 27, 6:24 pm ET
NEW YORK, Aug. 27 /PRNewswire-FirstCall/ -- Iconix Brand Group, Inc. (Nasdaq: ICON; "Iconix" or the "Company") today announced that it has signed an exclusive direct-to-retail license agreement with Wal-Mart for its Ocean Pacific ® and OP ® brands for distribution of a broad range of apparel and accessories in the United States. The agreement also grants Wal-Mart rights to use the brands in Brazil, China and India, and provides for the possible addition of license rights for other international territories in the future. The targeted launch date for the U.S. is Spring/Summer 2008.
Neil Cole, Chairman and CEO of Iconix commented, "Ocean Pacific is a wonderful brand with over thirty year of heritage and we are excited that the world's largest retailer, Wal-Mart, will now bring this global brand to the broadest audience of consumers in its history. We are looking forward to working with Wal-Mart to continue to develop Ocean Pacific into a year round lifestyle brand that we are confident will resonate deeply with the Wal-Mart customer."
Iconix Brand Group Inc. (Nasdaq: ICON - News) owns, licenses and markets a growing portfolio of consumer brands including CANDIE'S ®, BONGO ®, BADGLEY MISCHKA ®, JOE BOXER ® RAMPAGE ® MUDD ®, LONDON FOG ®, MOSSIMO ® OCEAN PACIFIC ®, DANSKIN ® and ROCA WEAR®. The Company licenses it brands to a network of leading retailers and manufacturers that touch every major segment of retail distribution from the luxury market to the mass market in both the U.S. and around the world. Iconix, through its in- house advertising, promotion and public relations agency, markets its brands to continually drive greater consumer awareness and equity.
Contact:
David Conn
Executive Vice President
Iconix Brand Group, Inc.
212-730-0030
--------------------------------------------------------------------------------
Source: Iconix Brand Group Inc.
http://biz.yahoo.com/prnews/070827/nym132.html?.v=83
ANSW (speaking of) is now a site I use pretty regularly. Although I haven't been impressed with how far the stock has
gone down (reflective of predicted 3 rd quarter loss as well) this may be good entry territory soon.
re: FAT CATS POSTER OF THE WEEK: Please PM me your nomination- honored poster to be announced Friday night.
Just give me a name and one or two reasons why. Thanks! :)
Free Posters: Just PM me during Happy hour after the bell on Friday
I found a new feature (change) on the site today as well.
Was this a treasure hunt? lol
Mark Cuban is going to be on Dancing With the Stars.
I read the spoiler alert a little bit ago.
I may actually watch this season........:)
"Sometimes people come to IHub and never leave until they die, like Marie(az2820).
http://www.investorshub.com/boards/profile.asp?user=18488
Others come and then publicly leave like Troy(WTMHouston).
http://www.investorshub.com/boards/profile.asp?user=4635
But there are some that come, make a lot of friends, and then,
BAM,
They are gone without a trace.
These are the posters that are Missing In Action."
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The "Ihubbers-Missing In Action" board........
http://investorshub.advfn.com/boards/board.asp?board_id=6478
You're very helpful today, g.
It was started by a poster who bashes Christians on the Christian board. I just looked thru his posting history
He seems so angry. Poor fella......
Matt: New board created that is created for personal attacks only........
http://investorshub.advfn.com/boards/board.asp?board_id=10295
FAT CATS POSTER OF THE WEEK: Please PM me your nomination- honored poster to be announced Friday night.
Just give me a name and one or two reasons why. Thanks! :)
Free Posters: Just PM me during Happy hour after the bell on Friday
Realtor, please save your banter for the parking lot or on PM.
We keep a nice board here and I'd like to keep it that way.
TOS rules apply.
Thanks!
BOARD: What is going on in SWVC? I just took a peek at some of the ihub stats and noted that the SWVC board has had over 41 thousand reads since midnight.
Any guesses? What is this company? I've not been introduced to the gossip there. tia
Seaway Valley Capt Corp ((SWVC))
thank you
Wow! CPSL, whadda day. Nice catch, Serfie.
BOARD SURVEY: (if you've never taken it, please do so. We'll be creating a new one based on the results of this) tia:
http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=3961
I have a copy that substitutes Basher for Pumper. It's really funny.
There is another copy out there for in-law and ex-boyfriend's new girlfriend. lol
can i be #5?
ONXX wowsa. Up over 12%. Way to go team with the picks this morning.
GERN: Up, but down from the opening gap. Link back for news and chart at bottom of my post.
lol, yup. Sept is going to be great- back in full swing for me as well.
out to lunch perhaps. No biggie, I'll be doing the same shortly.
what's good today, Tiki. Got any fab plays going on?
yup. ENXTF was a nice lil (4.76%) gain this morning. Not too wild, but bullish play. veddy good veddy good
Do you trade other stocks? Just curious if you've got any other plays. I'm interested here.
Not too friendly on the pinks anymore, but always open to new ideas. tia
unless folks are long, and really don't mind the volatility-
I'm uncertain how they can possibly trade the pinks without
L2.
After trying out several a few years ago (when testing my pinkie skills............)
Alphatrade gave me my free trial ago and hooked me right in with all the fancy doo-dads on it.
I typically don't have to delete much here. We cover pinks to blues, and I'm really not bias to any stock. I just call em like I see em and hope folks can respect that on this board.
aside from which- one warning should suffice among adults :)
No personal attacks please.
thank you..........
which reminds me.......time for a refill
ENXTF.OB 2.10- NXT Announces Signing of CDN $9.0 Million SFD Survey Contracts
Monday August 27, 9:00 am ET
CALGARY, ALBERTA--(MARKET WIRE)--Aug 27, 2007 -- Energy Exploration Technologies Inc. ("NXT" or "the Company") (OTC BB:ENXTF.OB - News)(Frankfurt:EFW.F - News) -
NXT is pleased to announce the signing of additional CDN $9.0 million Stress Field Detection ("SFD") survey contracts with an existing client. The client had previously contracted and paid NXT for a CDN $3.0 million survey, which was announced on December 6, 2006 and completed in June 2007. These new contracts will be conducted in following phases:
1. CDN $500,000 for additional interpretation services, commencing immediately;
2. CDN $1.0 million SFD survey, commencing immediately; and
3. CDN $7.5 million of unspecified additional SFD surveys commencing in the fourth quarter of 2007, subject to completion of client financing by October 15, 2007.
In addition to the contracted survey fees to be received as outlined above, NXT will also be entitled to a Gross Overriding Royalty Interest ("GORR") on any petroleum and natural gas production from lands developed by the client within the recommended SFD prospect areas.
"With the signing of this agreement NXT now has inventory of SFD survey work to provide assurance of continued revenue throughout the balance of 2007 and into 2008." said Ken Rogers, VP Finance and CFO. "Additionally as all flight operations are scheduled for completion in 2007 we anticipate strong cash flow for the year from progress payments."
NXT is in the business of providing wide-area airborne exploration services to the oil and gas industry. The Company utilizes its proprietary SFD Survey System to offer its clients a unique, low cost service to rapidly identify sub-surface structures with reservoir potential in sedimentary basins with no environmental impact. The value of the service is providing clients with an efficient, cost effective method of surveying large tracts of land and delivering an inventory of SFD prospects with high potential. The SFD-based exploration process substantially reduces the need for 2-D reconnaissance seismic thus saving clients' valuable time and money.
Additional information about NXT and the SFD technology is available on the Company's website www.nxtenergy.com.
Forward-Looking Statements
This news release may include forward-looking statements including opinions, assumptions, estimates and expectations of future prospects for the Company and financial projections. When used in this document, the words "anticipate," "believe," "estimate," "expect," "intend," "may," "project," "plan," "will," "should" and similar expressions are intended to be among the statements that identify forward-looking statements. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, the volatility of oil and gas prices, the ability to implement corporate strategies, the state of capital markets, the ability to obtain financing, changes in the oil and gas industry, operating risks, reserve estimates, changes in general economic conditions and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities.
Neither the NASDAQ OTCBB nor the Frankfurt or Berlin Exchanges have reviewed and do not accept responsibility for the adequacy or accuracy of this news release.
Contact:
Contacts:
Energy Exploration Technologies Inc.
Ken Rogers
VP Finance and CFO
(403) 264-7020
(403) 264-6442 (FAX)
Energy Exploration Technologies Inc.
505 - 3rd Street, S.W., Suite 1400
Calgary, Alberta, Canada T2P 3E6
Email: info@nxtenergy.com
Website: http://www.nxtenergy.com
--------------------------------------------------------------------------------
Source: Energy Exploration Technologies Inc.
http://biz.yahoo.com/iw/070827/0295179.html
{chart]stockcharts.com/c-sc/sc?s=ENXTF&p=D&yr=0&mn=3&dy=0&i=t47341170010&r=9500
Yikes!! UK Mortgage Market Reacts To US Crash
Monday August 27, 9:03 am ET
UK mortgage lenders withdraw lending from sub-prime market without notice as a direct consequence of the US sub prime market crash.
BOURNEMOUTH, England, Aug. 27 /PRNewswire/ -- The Council of Mortgage Lenders stated earlier this month that because of the "structural differences" between US lending and UK regulated lending the UK mortgage market would not be affected. However it has just been revealed that three UK lenders have simply pulled out of the sub-prime market without notice and this is giving rise to concerns that they may shortly be followed by main high street lenders.
First to go was DB Mortgages who have recently been followed by Unity Homeloans and Infinity Mortgages. All three lenders who play a large role in the sub-prime UK mortgage market have stated that their withdrawal is simply about "re-pricing" and that they intend to return to the market.
"I think the initial statements sent out by UK lenders council was slightly naive as a lot of the main US lenders have stakes in the UK market which means there will definitely be a knock-on effect. Hopefully the market won't go into panic about the recent withdrawals and cause a domino effect," said FancyAMortgage.co.uk company director Paul Giles.
FancyAMortgage.co.uk has seen an increase is user applications for a sub- prime mortgage quote since the US market crash which possibly means that users might be trying to 'get in quick' out of fear of a sub-prime market lending decline.
FancyAMortgage.co.uk
1 Richmond Hill,
Bournemouth,
Dorset
UK
BH2 6HE
www.FancyAMortgage.co.uk
info@FancyAMortgage.co.uk
Tel: 00 44(0)1202 310868
Fax: 00 44 (0)1202 311246
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
--------------------------------------------------------------------------------
Source: FancyAMortgage.co.uk
http://biz.yahoo.com/prnews/070827/aqm097.html?.v=18
Me. I'm just spamming it to all the pumpers.
You beat me on the post, lol.
(*thinly traded) HNIN.OB: .37 Horne International Subsidiary Signs 5-Year Contract with L-3 Communications
Monday August 27, 9:00 am ET
Spectrum Sciences & Software to Provide Precision Manufacturing Support
Shares Outstanding: 41.77M
Float: 34.05M
FAIRFAX, Va.--(BUSINESS WIRE)--Horne International, Inc. (OTCBB:HNIN - News) today announced that L-3 Communications and Spectrum Sciences & Software, Inc., have reached an agreement for Spectrum to produce precision-manufactured aircraft parts for L-3. Spectrum is a wholly owned subsidiary of Horne International, a leading program engineering and technology solutions company.
The five-year basic ordering agreement includes a two-year base period ending May 8, 2009, with three one-year mutual renewal options.
Spectrum initially will produce flat pattern aircraft parts from customer-provided material on high-precision water-jet machines. These parts will directly support L-3's current domestic and foreign military aircraft sales requirements. The orders placed over the first nine months of the contract will be ordered at guaranteed minimum monthly levels of work, and Spectrum will rapidly produce, inspect, package, and ship the finished parts back to the customer.
Spectrum provides expertise in the area of national defense, with core capabilities in the design and manufacture of aircraft and munitions support equipment. "Spectrum has an excellent track record of delivering high quality products on time and at competitive prices. This long-term contract with L-3 Communications -- the sixth-largest defense company in the United States -- is a testament to Spectrum's past performance under more than 850 contracts," said Darryl K. Horne, President, Chief Executive Officer and Chairman of Horne International. "We are enhancing Spectrum's manufacturing capabilities to help it meet future contracting opportunities in support of essential federal government requirements."
L-3 Communications is a leader and prime defense contractor in intelligence, surveillance and reconnaissance, secure communications, government services, training and simulation and aircraft modernization and maintenance. More information about L-3 can be found at www.L-3com.com.
About Horne International, Inc.
Horne International (OTCBB:HNIN - News) delivers uniquely engineered solutions that advance some of today's foremost agendas -- winning the war on terrorism, strengthening national security, and fostering environmental sustainability. Service areas include program engineering; technology; manufacturing; maritime and industrial repair; environment, safety, and health; acquisition services; public outreach; and business process engineering. More information can be found at www.horne.com.
Forward-Looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, risks set forth in documents filed by the company from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by, or on behalf of, the Company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Horne International, Inc.
Media Contact:
William Maly, 703-641-1100
wmaly@horne.com
--------------------------------------------------------------------------------
Source: Horne International, Inc.
http://biz.yahoo.com/bw/070827/20070827005168.html?.v=1
Great alert :)
BRL : 52.14- Upgrade on Friday and news of sales (chart)
GERN: 6.89 (starting to move p/m) Geron Scientists and Collaborators Demonstrate Human Embryonic Stem Cell-Derived Cardiomyocytes Improve Heart Function When Transplanted After Myocardial Infarction
Monday August 27, 7:30 am ET
Landmark Study Published in Nature Biotechnology is First to Show Heart Repair by Cardiomyocytes Produced from Human Embryonic Stem Cells
Data Demonstrate Human Cardiac Cell Survival in Infarct Zone, Resulting in Improved Cardiac Structure and Contractile Function
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.
Published online Aug. 26 in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct. In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.
The study describes the feeder- and serum-free, scalable production of hESC-derived cardiomyocytes, their survival in the infarct zone of rats when transplanted four days after infarction, and echocardiographic and MRI evidence of significant improvement in cardiac structure and contractile function. Geron's scientists conducted the study in collaboration with Charles Murry, M.D., Ph.D., and Michael Laflamme, M.D., Ph.D., at the University of Washington.
"This is one of the most important publications on hESCs for Geron to date," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "Our cardiomyocytes are the first human cardiac cells shown to survive after injection into an infarcted ventricle and to produce significant improvement in heart function. hESCs are the only cell type shown definitively to form cardiomyocytes."
Approximately 5.2 million people in the United States suffer from heart failure, and approximately 865,000 people experience myocardial infarction each year. About 36% of this population progresses to heart failure within five years of a first infarction. More than one-third of all heart failure patients die within two years of diagnosis.
"We're developing our cardiomyocyte product, GRNCM1, to address the large unmet need in heart failure," Dr. Okarma added. "We expect GRNCM1 to be our second hESC-derived cell type to enter clinical development."
Production and Characterization of hESC-derived Cardiomyocytes
In the study, researchers produced human cardiomyocytes from hESCs using a sequential, directed differentiation protocol that did not rely on serum or feeder cells. The procedure was scalable and efficient, with each hESC producing approximately three human cardiomyocytes. After final enrichment, greater than 80% of the cells were cardiomyocytes. The hESC-derived cardiomyocytes displayed surface and intracellular markers, as well as electrophysiologic and pharmacologic properties consistent with human cardiomyocytes, the majority of which represented ventricular cardiomyocytes.
Engraftment Following Transplantation
To enable survival in the heart, the hESC-derived cardiomyocytes were suspended in a cocktail of survival factors that had been experimentally determined to dramatically enhance cell survival after injection into the infarcted ventricular wall. Four weeks later, tissue sections from the infarcted hearts were examined for the presence of the human cells. The vast majority of human cardiomyocytes were localized in the central region of the infarct, suggesting that the cells were capable of engraftment in the hostile environment of the infarct zone. Moreover, a portion of the cardiomyocytes was mitotic after injection, possibly enhancing their regenerative efficiency. The grafts also induced a brisk, host-derived angiogenic response: all the implants contained numerous capillaries lined with rat endothelial cells.
Safety
No teratomas, tumor masses, or aberrant structures were seen in any of the hearts receiving hESC-derived cardiomyocytes. A highly sensitive PCR assay was used to determine whether any hESC-derived cells had migrated to other non-cardiac organs. None were detected in brain, kidney, liver, lung or spleen, indicating the absence of migration of the injected cells from the heart.
Impact of Transplanted hESC-derived Cardiomyocytes on Cardiac Structure and Function
To assess the impact of injected cells on cardiac structure and function, all animals received echocardiography at baseline (two days after infarction but two days prior to cell injection) and at four weeks post cardiomyocyte implantation. All animals exhibited significant cardiac dysfunction two days post infarct. On average, left-ventricular end diastolic and systolic diameters increased by 10% and 42%, respectively, and fractional shortening decreased by 40% compared to uninfarcted controls.
Four days after infarction, animals were injected with 10 million hESC-derived cardiomyocytes suspended in the survival cocktail. Animals injected with either the survival cocktail alone, serum-free media without cells, or equivalent numbers of non-cardiac hESC-derived cells suspended in the survival cocktail served as control groups.
Echocardiography performed four weeks after cell implantation showed attenuation of left-ventricular end-diastolic and end-systolic diameters in animals receiving cardiomyocytes versus all three control groups. In addition, fractional shortening was significantly improved (p less than 0.01) in animals that received cardiomyocytes compared to all three control groups. MRI analysis showed improved left-ventricular ejection fraction (p=0.05) in the cardiomyocyte-treated rats compared to controls, as well as a 2.5-fold increase in systolic wall thickening in the infarct zone relative to controls (p less than 0.01).
Significance
This study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the infarct zone of the heart. The survival cocktail administered with the cells enables their long-term survival in the infarcted muscle. The injected cells stimulate endogenous blood vessel formation, possibly contributing to both cell survival and improved contractile function. The scalable production system allows for production runs at sufficient scale for large animal studies (ongoing) as well as for ultimate testing in humans.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended June 30, 2007.
Contact:
Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com
or
Russo Partners, LLC
David Schull, 858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@russopartnersllc.com
--------------------------------------------------------------------------------
Source: Geron Corporation
http://biz.yahoo.com/bw/070827/20070827005118.html?.v=1
RE: ETC: 3.24 -
Shares Outstanding: 9.03M
Float: 3.93M